APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenzavirus B Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Influenzavirus B Infection Drug Industry Research Report 2026

19 December 2025146 pages

Choose your research edition.

Industry ResearchInfluenzavirus B Infection Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Influenzavirus B Infection Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Influenzavirus B Infection Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Influenzavirus B Infection Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Influenzavirus B Infection Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Influenzavirus B Infection Drug Market by Company

Sanofi

AbbVie Inc

Vectura Group Plc

Vaxart Inc

TSRL Inc

SK Chemicals Co Ltd

Shionogi & Co Ltd

Sanofi Pasteur SA

Romark Laboratories LC

Park Active Molecules

Novavax Inc

Mucosis BV

MedImmune LLC

Medicago Inc

Kineta Inc

Inovio Pharmaceuticals Inc

Green Cross Corp

GlaxoSmithKline Plc

Fujifilm Holdings Corporation

Daiichi Sankyo Company Ltd

ContraFect Corp

Cadila Healthcare Ltd

BioCryst Pharmaceuticals Inc

Aphios Corp

Amarillo Biosciences Inc

Altravax Inc

Adimmune Corp

Influenzavirus B Infection Drug Segment by Type

KIN-1400

GC-3106A

CF-403

APP-309

Others

Influenzavirus B Infection Drug Segment by Application

Clinic

Hospital

Others

Influenzavirus B Infection Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Influenzavirus B Infection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Influenzavirus B Infection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Influenzavirus B Infection Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Influenzavirus B Infection Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Influenzavirus B Infection Drug Revenue of Manufacturers (2021-2026) Table 9. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Influenzavirus B Infection Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Influenzavirus B Infection Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Influenzavirus B Infection Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Influenzavirus B Infection Drug, Product Type & Application Table 14. Global Influenzavirus B Infection Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Influenzavirus B Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi Influenzavirus B Infection Drug Product Portfolio Table 22. Sanofi Recent Developments Table 23. AbbVie Inc Company Information Table 24. AbbVie Inc Business Overview Table 25. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio Table 27. AbbVie Inc Recent Developments Table 28. Vectura Group Plc Company Information Table 29. Vectura Group Plc Business Overview Table 30. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio Table 32. Vectura Group Plc Recent Developments Table 33. Vaxart Inc Company Information Table 34. Vaxart Inc Business Overview Table 35. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio Table 37. Vaxart Inc Recent Developments Table 38. TSRL Inc Company Information Table 39. TSRL Inc Business Overview Table 40. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. TSRL Inc Influenzavirus B Infection Drug Product Portfolio Table 42. TSRL Inc Recent Developments Table 43. SK Chemicals Co Ltd Company Information Table 44. SK Chemicals Co Ltd Business Overview Table 45. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 47. SK Chemicals Co Ltd Recent Developments Table 48. Shionogi & Co Ltd Company Information Table 49. Shionogi & Co Ltd Business Overview Table 50. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 52. Shionogi & Co Ltd Recent Developments Table 53. Sanofi Pasteur SA Company Information Table 54. Sanofi Pasteur SA Business Overview Table 55. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio Table 57. Sanofi Pasteur SA Recent Developments Table 58. Romark Laboratories LC Company Information Table 59. Romark Laboratories LC Business Overview Table 60. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio Table 62. Romark Laboratories LC Recent Developments Table 63. Park Active Molecules Company Information Table 64. Park Active Molecules Business Overview Table 65. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio Table 67. Park Active Molecules Recent Developments Table 68. Novavax Inc Company Information Table 69. Novavax Inc Business Overview Table 70. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novavax Inc Influenzavirus B Infection Drug Product Portfolio Table 72. Novavax Inc Recent Developments Table 73. Mucosis BV Company Information Table 74. Mucosis BV Business Overview Table 75. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Mucosis BV Influenzavirus B Infection Drug Product Portfolio Table 77. Mucosis BV Recent Developments Table 78. MedImmune LLC Company Information Table 79. MedImmune LLC Business Overview Table 80. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio Table 82. MedImmune LLC Recent Developments Table 83. Medicago Inc Company Information Table 84. Medicago Inc Business Overview Table 85. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Medicago Inc Influenzavirus B Infection Drug Product Portfolio Table 87. Medicago Inc Recent Developments Table 88. Kineta Inc Company Information Table 89. Kineta Inc Business Overview Table 90. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Kineta Inc Influenzavirus B Infection Drug Product Portfolio Table 92. Kineta Inc Recent Developments Table 93. Inovio Pharmaceuticals Inc Company Information Table 94. Inovio Pharmaceuticals Inc Business Overview Table 95. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 97. Inovio Pharmaceuticals Inc Recent Developments Table 98. Green Cross Corp Company Information Table 99. Green Cross Corp Business Overview Table 100. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio Table 102. Green Cross Corp Recent Developments Table 103. GlaxoSmithKline Plc Company Information Table 104. GlaxoSmithKline Plc Business Overview Table 105. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio Table 107. GlaxoSmithKline Plc Recent Developments Table 108. Fujifilm Holdings Corporation Company Information Table 109. Fujifilm Holdings Corporation Business Overview Table 110. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio Table 112. Fujifilm Holdings Corporation Recent Developments Table 113. Daiichi Sankyo Company Ltd Company Information Table 114. Daiichi Sankyo Company Ltd Business Overview Table 115. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio Table 117. Daiichi Sankyo Company Ltd Recent Developments Table 118. ContraFect Corp Company Information Table 119. ContraFect Corp Business Overview Table 120. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio Table 122. ContraFect Corp Recent Developments Table 123. Cadila Healthcare Ltd Company Information Table 124. Cadila Healthcare Ltd Business Overview Table 125. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio Table 127. Cadila Healthcare Ltd Recent Developments Table 128. BioCryst Pharmaceuticals Inc Company Information Table 129. BioCryst Pharmaceuticals Inc Business Overview Table 130. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 132. BioCryst Pharmaceuticals Inc Recent Developments Table 133. Aphios Corp Company Information Table 134. Aphios Corp Business Overview Table 135. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Aphios Corp Influenzavirus B Infection Drug Product Portfolio Table 137. Aphios Corp Recent Developments Table 138. Amarillo Biosciences Inc Company Information Table 139. Amarillo Biosciences Inc Business Overview Table 140. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio Table 142. Amarillo Biosciences Inc Recent Developments Table 143. Altravax Inc Company Information Table 144. Altravax Inc Business Overview Table 145. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Altravax Inc Influenzavirus B Infection Drug Product Portfolio Table 147. Altravax Inc Recent Developments Table 148. Adimmune Corp Company Information Table 149. Adimmune Corp Business Overview Table 150. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio Table 152. Adimmune Corp Recent Developments Table 153. Global Influenzavirus B Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 154. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (K Units) Table 155. Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2026) Table 156. Global Influenzavirus B Infection Drug Sales by Region (2027-2032) & (K Units) Table 157. Global Influenzavirus B Infection Drug Sales Market Share by Region (2027-2032) Table 158. Global Influenzavirus B Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 159. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2026) Table 160. Global Influenzavirus B Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 161. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2027-2032) Table 162. North America Influenzavirus B Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. North America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 164. North America Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 165. North America Influenzavirus B Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 166. North America Influenzavirus B Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 167. Europe Influenzavirus B Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Europe Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 169. Europe Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 170. Europe Influenzavirus B Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 171. Europe Influenzavirus B Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 172. Asia Pacific Influenzavirus B Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 174. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 175. Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 176. Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 177. South America Influenzavirus B Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. South America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 179. South America Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 180. South America Influenzavirus B Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 181. South America Influenzavirus B Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 182. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 184. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 185. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 186. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 187. Global Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 188. Global Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 189. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2026) Table 190. Global Influenzavirus B Infection Drug Sales Market Share by Type (2027-2032) Table 191. Global Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 192. Global Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 193. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2026) Table 194. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2027-2032) Table 195. Global Influenzavirus B Infection Drug Price by Type (2021-2026) & (US$/Unit) Table 196. Global Influenzavirus B Infection Drug Price by Type (2027-2032) & (US$/Unit) Table 197. Global Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 198. Global Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 199. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2026) Table 200. Global Influenzavirus B Infection Drug Sales Market Share by Application (2027-2032) Table 201. Global Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 202. Global Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 203. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2026) Table 204. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2027-2032) Table 205. Global Influenzavirus B Infection Drug Price by Application (2021-2026) & (US$/Unit) Table 206. Global Influenzavirus B Infection Drug Price by Application (2027-2032) & (US$/Unit) Table 207. Key Raw Materials Table 208. Raw Materials Key Suppliers Table 209. Influenzavirus B Infection Drug Distributors List Table 210. Influenzavirus B Infection Drug Customers List Table 211. Influenzavirus B Infection Drug Industry Trends Table 212. Influenzavirus B Infection Drug Industry Drivers Table 213. Influenzavirus B Infection Drug Industry Restraints Table 214. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Influenzavirus B Infection Drug Product Image Figure 5. Global Influenzavirus B Infection Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Influenzavirus B Infection Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Influenzavirus B Infection Drug Sales (2021-2032) & (K Units) Figure 8. Global Influenzavirus B Infection Drug Average Price (US$/Unit) & (2021-2032) Figure 9. KIN-1400 Product Image Figure 10. GC-3106A Product Image Figure 11. CF-403 Product Image Figure 12. APP-309 Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Others Product Image Figure 17. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Influenzavirus B Infection Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Influenzavirus B Infection Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Influenzavirus B Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Influenzavirus B Infection Drug Sales by Region in 2025 Figure 23. Global Influenzavirus B Infection Drug Revenue by Region in 2025 Figure 24. North America Influenzavirus B Infection Drug Market Size by Country in 2025 Figure 25. North America Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 26. North America Influenzavirus B Infection Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Influenzavirus B Infection Drug Market Size by Country in 2025 Figure 30. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Influenzavirus B Infection Drug Market Size by Country in 2025 Figure 38. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Country (2021-2032) Figure 40. China Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Influenzavirus B Infection Drug Market Size by Country in 2025 Figure 49. South America Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 50. South America Influenzavirus B Infection Drug Revenue Market Share by Country (2021-2032) Figure 51. Mexico Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Influenzavirus B Infection Drug Market Size by Country in 2025 Figure 55. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2021-2032) Figure 57. Turkey Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Influenzavirus B Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032) Figure 61. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032) Figure 62. Global Influenzavirus B Infection Drug Price (US$/Unit) by Type (2021-2032) Figure 63. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032) Figure 64. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032) Figure 65. Global Influenzavirus B Infection Drug Price (US$/Unit) by Application (2021-2032) Figure 66. Influenzavirus B Infection Drug Value Chain Figure 67. Influenzavirus B Infection Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Influenzavirus B Infection Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • KIN-1400
  • GC-3106A
  • CF-403
  • APP-309
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sanofi
  • AbbVie Inc
  • Vectura Group Plc
  • Vaxart Inc
  • TSRL Inc
  • SK Chemicals Co Ltd
  • Shionogi & Co Ltd
  • Sanofi Pasteur SA
  • Romark Laboratories LC
  • Park Active Molecules
  • Novavax Inc
  • Mucosis BV
  • MedImmune LLC
  • Medicago Inc
  • Kineta Inc
  • Inovio Pharmaceuticals Inc
  • Green Cross Corp
  • GlaxoSmithKline Plc
  • Fujifilm Holdings Corporation
  • Daiichi Sankyo Company Ltd
  • ContraFect Corp
  • Cadila Healthcare Ltd
  • BioCryst Pharmaceuticals Inc
  • Aphios Corp
  • Amarillo Biosciences Inc
  • Altravax Inc
  • Adimmune Corp

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Influenzavirus B Infection Drug Market Size (2021-2032)
  4. 2.2.2 Global Influenzavirus B Infection Drug Sales (2021-2032)
  5. 2.2.3 Global Influenzavirus B Infection Drug Market Average Price (2021-2032)
  6. 2.3 Influenzavirus B Infection Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 KIN-1400
  9. 2.3.3 GC-3106A
  10. 2.3.4 CF-403
  11. 2.3.5 APP-309
  12. 2.3.6 Others
  13. 2.4 Influenzavirus B Infection Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Influenzavirus B Infection Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Influenzavirus B Infection Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Influenzavirus B Infection Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Influenzavirus B Infection Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Influenzavirus B Infection Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Influenzavirus B Infection Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Influenzavirus B Infection Drug, Established Date
  9. 3.9 Global Influenzavirus B Infection Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 AbbVie Inc
  8. 4.2.1 AbbVie Inc Company Information
  9. 4.2.2 AbbVie Inc Business Overview
  10. 4.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
  12. 4.2.5 AbbVie Inc Recent Developments
  13. 4.3 Vectura Group Plc
  14. 4.3.1 Vectura Group Plc Company Information
  15. 4.3.2 Vectura Group Plc Business Overview
  16. 4.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
  18. 4.3.5 Vectura Group Plc Recent Developments
  19. 4.4 Vaxart Inc
  20. 4.4.1 Vaxart Inc Company Information
  21. 4.4.2 Vaxart Inc Business Overview
  22. 4.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
  24. 4.4.5 Vaxart Inc Recent Developments
  25. 4.5 TSRL Inc
  26. 4.5.1 TSRL Inc Company Information
  27. 4.5.2 TSRL Inc Business Overview
  28. 4.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
  30. 4.5.5 TSRL Inc Recent Developments
  31. 4.6 SK Chemicals Co Ltd
  32. 4.6.1 SK Chemicals Co Ltd Company Information
  33. 4.6.2 SK Chemicals Co Ltd Business Overview
  34. 4.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
  36. 4.6.5 SK Chemicals Co Ltd Recent Developments
  37. 4.7 Shionogi & Co Ltd
  38. 4.7.1 Shionogi & Co Ltd Company Information
  39. 4.7.2 Shionogi & Co Ltd Business Overview
  40. 4.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
  42. 4.7.5 Shionogi & Co Ltd Recent Developments
  43. 4.8 Sanofi Pasteur SA
  44. 4.8.1 Sanofi Pasteur SA Company Information
  45. 4.8.2 Sanofi Pasteur SA Business Overview
  46. 4.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
  48. 4.8.5 Sanofi Pasteur SA Recent Developments
  49. 4.9 Romark Laboratories LC
  50. 4.9.1 Romark Laboratories LC Company Information
  51. 4.9.2 Romark Laboratories LC Business Overview
  52. 4.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
  54. 4.9.5 Romark Laboratories LC Recent Developments
  55. 4.10 Park Active Molecules
  56. 4.10.1 Park Active Molecules Company Information
  57. 4.10.2 Park Active Molecules Business Overview
  58. 4.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
  60. 4.10.5 Park Active Molecules Recent Developments
  61. 4.11 Novavax Inc
  62. 4.11.1 Novavax Inc Company Information
  63. 4.11.2 Novavax Inc Business Overview
  64. 4.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
  66. 4.11.5 Novavax Inc Recent Developments
  67. 4.12 Mucosis BV
  68. 4.12.1 Mucosis BV Company Information
  69. 4.12.2 Mucosis BV Business Overview
  70. 4.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
  72. 4.12.5 Mucosis BV Recent Developments
  73. 4.13 MedImmune LLC
  74. 4.13.1 MedImmune LLC Company Information
  75. 4.13.2 MedImmune LLC Business Overview
  76. 4.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
  78. 4.13.5 MedImmune LLC Recent Developments
  79. 4.14 Medicago Inc
  80. 4.14.1 Medicago Inc Company Information
  81. 4.14.2 Medicago Inc Business Overview
  82. 4.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
  84. 4.14.5 Medicago Inc Recent Developments
  85. 4.15 Kineta Inc
  86. 4.15.1 Kineta Inc Company Information
  87. 4.15.2 Kineta Inc Business Overview
  88. 4.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
  90. 4.15.5 Kineta Inc Recent Developments
  91. 4.16 Inovio Pharmaceuticals Inc
  92. 4.16.1 Inovio Pharmaceuticals Inc Company Information
  93. 4.16.2 Inovio Pharmaceuticals Inc Business Overview
  94. 4.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  96. 4.16.5 Inovio Pharmaceuticals Inc Recent Developments
  97. 4.17 Green Cross Corp
  98. 4.17.1 Green Cross Corp Company Information
  99. 4.17.2 Green Cross Corp Business Overview
  100. 4.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
  102. 4.17.5 Green Cross Corp Recent Developments
  103. 4.18 GlaxoSmithKline Plc
  104. 4.18.1 GlaxoSmithKline Plc Company Information
  105. 4.18.2 GlaxoSmithKline Plc Business Overview
  106. 4.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
  108. 4.18.5 GlaxoSmithKline Plc Recent Developments
  109. 4.19 Fujifilm Holdings Corporation
  110. 4.19.1 Fujifilm Holdings Corporation Company Information
  111. 4.19.2 Fujifilm Holdings Corporation Business Overview
  112. 4.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
  114. 4.19.5 Fujifilm Holdings Corporation Recent Developments
  115. 4.20 Daiichi Sankyo Company Ltd
  116. 4.20.1 Daiichi Sankyo Company Ltd Company Information
  117. 4.20.2 Daiichi Sankyo Company Ltd Business Overview
  118. 4.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
  120. 4.20.5 Daiichi Sankyo Company Ltd Recent Developments
  121. 4.21 ContraFect Corp
  122. 4.21.1 ContraFect Corp Company Information
  123. 4.21.2 ContraFect Corp Business Overview
  124. 4.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
  126. 4.21.5 ContraFect Corp Recent Developments
  127. 4.22 Cadila Healthcare Ltd
  128. 4.22.1 Cadila Healthcare Ltd Company Information
  129. 4.22.2 Cadila Healthcare Ltd Business Overview
  130. 4.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
  132. 4.22.5 Cadila Healthcare Ltd Recent Developments
  133. 4.23 BioCryst Pharmaceuticals Inc
  134. 4.23.1 BioCryst Pharmaceuticals Inc Company Information
  135. 4.23.2 BioCryst Pharmaceuticals Inc Business Overview
  136. 4.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  138. 4.23.5 BioCryst Pharmaceuticals Inc Recent Developments
  139. 4.24 Aphios Corp
  140. 4.24.1 Aphios Corp Company Information
  141. 4.24.2 Aphios Corp Business Overview
  142. 4.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
  144. 4.24.5 Aphios Corp Recent Developments
  145. 4.25 Amarillo Biosciences Inc
  146. 4.25.1 Amarillo Biosciences Inc Company Information
  147. 4.25.2 Amarillo Biosciences Inc Business Overview
  148. 4.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
  150. 4.25.5 Amarillo Biosciences Inc Recent Developments
  151. 4.26 Altravax Inc
  152. 4.26.1 Altravax Inc Company Information
  153. 4.26.2 Altravax Inc Business Overview
  154. 4.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
  156. 4.26.5 Altravax Inc Recent Developments
  157. 4.27 Adimmune Corp
  158. 4.27.1 Adimmune Corp Company Information
  159. 4.27.2 Adimmune Corp Business Overview
  160. 4.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
  162. 4.27.5 Adimmune Corp Recent Developments
5 Global Influenzavirus B Infection Drug Market Scenario by Region
  1. 5.1 Global Influenzavirus B Infection Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Influenzavirus B Infection Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Influenzavirus B Infection Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Influenzavirus B Infection Drug Sales by Region: 2027-2032
  5. 5.3 Global Influenzavirus B Infection Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Influenzavirus B Infection Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Influenzavirus B Infection Drug Revenue by Region: 2027-2032
  8. 5.4 North America Influenzavirus B Infection Drug Market Facts & Figures by Country
  9. 5.4.1 North America Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Influenzavirus B Infection Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Influenzavirus B Infection Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Influenzavirus B Infection Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Influenzavirus B Infection Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Influenzavirus B Infection Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Influenzavirus B Infection Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Influenzavirus B Infection Drug Market Facts & Figures by Country
  35. 5.7.1 South America Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Influenzavirus B Infection Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Influenzavirus B Infection Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Influenzavirus B Infection Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Influenzavirus B Infection Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Influenzavirus B Infection Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Influenzavirus B Infection Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Influenzavirus B Infection Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Influenzavirus B Infection Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Influenzavirus B Infection Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Influenzavirus B Infection Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Influenzavirus B Infection Drug Value Chain Analysis
  2. 8.1.1 Influenzavirus B Infection Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Influenzavirus B Infection Drug Production Mode & Process
  5. 8.2 Influenzavirus B Infection Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Influenzavirus B Infection Drug Distributors
  8. 8.2.3 Influenzavirus B Infection Drug Customers
9 Global Influenzavirus B Infection Drug Analyzing Market Dynamics
  1. 9.1 Influenzavirus B Infection Drug Industry Trends
  2. 9.2 Influenzavirus B Infection Drug Industry Drivers
  3. 9.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
  4. 9.4 Influenzavirus B Infection Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst